About Illumigen
Illumigen is a Healthcare company based in Osaka (Japan) founded in 2000, and was acquired by Cubist Pharmaceuticals in December 2007. Therapeutics for infectious diseases were developed by US-based Illumigen. Illumigen has raised $956.85 thousand across 1 funding round from investors including Cubist Pharmaceuticals. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Illumigen was established in 2000 as a pharmaceutical company based in the United States. Focus was placed on developing treatments for infectious conditions, such as hepatitis C virus, respiratory syncytial virus, and related areas including obesity. Drug candidates were advanced through research and preclinical stages. Acquisition by Cubist Pharmaceuticals took place in December 2007, after which independent operations ceased.
- Headquarters Osaka, Japan
- Stage Acquired
- SectorsHealthcare
- Website illumigen.com
- Acquired by Cubist Pharmaceuticals (Dec 2007)
- Total Equity Funding$956.85K (USD)
in 1 rounds
- Latest Funding Round$956.85K (USD), Seed
Oct 2007
- Investors
- Acquired byCubist Pharmaceuticals
(Dec 2007)
Funding Insights of Illumigen
Illumigen has successfully raised a total of $956.85K through 1 strategic funding round. The most recent funding activity was a Seed round of $956.85 thousand completed in October 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $956,845
- Total Rounds 1
- Last Round Seed — $956,845
- First Round $956,845
(Oct 2007)
All 1 funding rounds of Illumigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2007 | $956,845 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Illumigen
Illumigen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cubist Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals for acute care bacterial infections are developed and commercialized. | 1993 | cubist.com | Lexington, United States |
Investor details for Illumigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Illumigen
3 dated milestones of Illumigen across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Illumigen is founded.
- Funding First funding round of $957K.
- Exit Acquired by Cubist Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Illumigen
Illumigen was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Illumigen is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
Illumigen is a funded company, having raised a total of $956.85K across 1 funding round to date. The company's 1st funding round was a Seed of $956.85K, raised on Oct 2007.
Illumigen was established in 2000 as a pharmaceutical company based in the United States. Focus was placed on developing treatments for infectious conditions, such as hepatitis C virus, respiratory syncytial virus, and related areas including obesity. Drug candidates were advanced through research and preclinical stages. Acquisition by Cubist Pharmaceuticals took place in December 2007, after which independent operations ceased.
Illumigen has 1 investor. Key investors include Cubist Pharmaceuticals.
Yes. Illumigen was acquired by Cubist Pharmaceuticals in December 2007.